The Energy Code

Resveratrol’s “Upgrade”? Resveratrone Might Be a Next-Gen Skin Longevity Molecule

This Deep Dive introduces resveratrone, a newly described compound created via photoconversion of resveratrol. The paper’s core argument is that resveratrone is structurally distinct enough to behave like a different molecule — and in a suite of skin-relevant assays (antioxidant capacity, melanin/tyrosinase biology, fibroblast activity, collagen synthesis, and acne-associated antimicrobial effects), it often outperforms resveratrol. Importantly, this is not a long-term human outcomes study; it’s an early mechanistic/performance comparison. Still, the profile is compelling: unusually strong DPPH radical scavenging (even compared to vitamin C under the reported conditions), measurable pigment-pathway effects, a notable signal around fibroblasts + type I collagen, and stronger inhibition of acne-associated bacteria. The episode closes with the right stance: promising signal → needs independent replication, formulation/penetration data, and clinical validation.

(Educational content only, not medical advice.)

-

Article Discussed in Episode:

Unveiling Resveratrone: A High-Performance Antioxidant Substance

-

Key Quotes From Dr. Mike:

“It is centered on a compound called resveratrone, which was discovered through the photoconversion of resveratrol.”

“When structure changes, biologic behavior can change dramatically—and that’s the entire premise here.”

“In most of these areas, resveratrone outperformed resveratrol.”

“Resveratrone showed extremely strong radical scavenging activity, even at low concentrations... It also outperformed ascorbic acid, vitamin C, under the same testing conditions.”

“It does not establish optimal topical formulation, stability over time, skin penetration in vivo, or ideal dosing.”

-

Key Points

• Resveratrone is discovered via photoconversion of resveratrol and may behave as a different molecule, not a minor variant.

• This is early-stage evidence: biochemical/cellular assays, not long-term human clinical outcomes.

• Antioxidant capacity: strong DPPH radical scavenging; reported to beat resveratrol and even vitamin C in the assay conditions.

• Pigment biology: reduces melanin in α-MSH–stimulated B16F10 cells; includes tyrosinase inhibition signal.

• Nuance: the paper notes not every endpoint is uniformly superior in all comparisons (some whitening comparisons are mixed).

• Regeneration signals: resveratrone increased fibroblast proliferation/activity and type I collagen synthesiswhere resveratrol did not in the same conditions (per the paper).

• Antimicrobial: stronger inhibition against acne-associated bacteria than resveratrol under the tested conditions.

• Practical framing: potential multifunctional skin active (antioxidant + pigment + collagen + microbiome stress support).

• Real-world translation questions: stability, penetration, dosing, safety, and performance in 3D skin/animal/clinical models.

• Conflict-of-interest disclosure exists → treat as promising, but prioritize independent replication.

-

Episode timeline

• 0:19–1:34 — Setup: why a resveratrol-derived “new molecule” matters

• 1:34–2:29 — Important framing: mechanistic/performance paper, not long-term clinical outcomes

• 2:35–3:35 — Discovery & premise: photoconversion changes structure → test as its own compound

• 3:14–3:47 — Endpoints tested: antioxidant, pigment/tyrosinase, fibroblasts/collagen, acne bacteria

• 4:00–5:46 — Antioxidant headline: DPPH potency; claims vs resveratrol and vitamin C

• 5:46–7:27 — Melanin suppression + tyrosinase activity; comparison context (incl. arbutin mention)

• 7:40–8:16 — Nuance: not every “whitening” comparison is universally dominant

• 8:27–10:44 — Fibroblasts + type I collagen: where the molecule looks qualitatively different

• 10:52–11:41 — Antibacterial activity: acne-associated bacteria inhibition

• 12:02–13:14 — Caution & credibility: early-stage paper + COI disclosure → need replication

• 13:47–16:17 — Synthesis: why structure ≠ name; “optimized familiar molecule” thesis + next questions

• 16:17–17:01 — Close: what would make this clinically meaningful

-

Dr. Mike's #1 recommendations:

Deuterium depleted water: Litewater (code: DRMIKE)

EMF-mitigating products: Somavedic (code: BIOLIGHT)

Blue light blocking glasses: Ra Optics (code: BIOLIGHT)

Grounding products: Earthing.com

-

Stay up-to-date on social media:

Dr. Mike Belkowski:

Instagram

LinkedIn

 

BioLight:

Website

Instagram

YouTube

Facebook

Photoaging is a Bioenergetic Problem: How Wrinkles via Sunlight Are Mitochondrial Damage Made Visible

This Deep Dive breaks photoaging out of the “cosmetic” category and reframes it as a systems-level loss of cellular resilience driven by ultraviolet exposure and mitochondrial stress. UVA and UVB create different injury patterns — UVB skewing toward more direct DNA damage in the epidermis, UVA driving deeper dermal oxidative stress that impacts fibroblasts and collagen architecture. The paper’s central thesis is bidirectional: UV damages mitochondria, and damaged mitochondria amplify UV injury through ROS, which creates a self-reinforcing loop that accelerates senescence, apoptosis, and matrix breakdown. The practical future of anti-photoaging therapy, according to this review, is mitochondria-forward: protect mtDNA, reduce ROS at the source, preserve membrane potential, and support mitochondrial quality control (especially mitophagy).

(Educational content only, not medical advice.)

-

Article Discussed in Episode:

Interplay of Skin Aging: Mitochondrial Stress and Ultraviolet Exposure

-

Key Quotes From Dr. Mike:

“Sun exposure does not just age the skin from the outside in, it ages the skin from the inside out.”

“Photoaging… is a bioenergetic event.”

“It is a vicious cycle between ultraviolet exposure and mitochondrial dysfunction with reactive oxygen species… as one of the key amplifiers of damage.”

“The authors described this as bidirectional… UV exposure damages mitochondria, but damaged mitochondria also amplify UV induced injury.”

“Wrinkles are not just wrinkles, they may be the visible endpoint of cumulative mitochondrial injury.”

“If that is true, then the future… may depend less on masking damage and more on restoring mitochondrial resilience.”

-

Key Points

• Photoaging is inside-out: UV triggers mitochondrial stress that amplifies aging biology.

• UVA vs UVB: UVA penetrates deeper → dermal oxidative stress; UVB → higher-energy, more direct DNA injury.

• Mitochondria are stress integrators, not just ATP producers (redox, apoptosis, calcium, dynamics, mitophagy).

• Core loop: UV → ROS → mtDNA/protein/membrane damage → impaired mitochondria → more ROS → accelerated decline.

• mtDNA injury is central (including the “common deletion” 4,977 bp, plus mutations/D-loop lesions/heteroplasmy).

• Downstream consequences include apoptosis (BCL-2 family shift → cytochrome c → caspases) and tissue-level fibroblast loss.

• Mitophagy (PINK1/Parkin) is protective; dysregulation leaves damaged mitochondria as chronic ROS generators.

• Regenerative directions discussed: stem-cell–derived exosomes that may support PINK1/Parkin mitophagy.

• Precision interventions highlighted: mitochondria-targeted antioxidants (MitoQ), specific peptides (e.g., “PWH”), and melatonin as a mitochondrial-relevant molecule.

• Future model: not just sunscreen + generic antioxidants—mitochondrial resilience as the real anti-aging strategy.

-

Episode timeline

• 0:19–1:51 — Why this paper matters: UV + mitochondrial stress + accelerated aging

• 2:11–3:44 — UVA vs UVB: depth, layer-specific injury patterns, and why wavelength matters

• 3:49–4:30 — Photoaging vs chronological aging: why “extrinsic aging” is modifiable

• 4:33–6:59 — Mitochondria as stress integrators; dynamics (DRP1, MFN1/2, OPA1) and what dysregulation implies

• 7:08–8:10 — The bidirectional loop: UV damages mitochondria; damaged mitochondria amplify UV injury

• 8:15–9:59 — mtDNA vulnerability: common deletion, mutations, heteroplasmy, bioenergetic thresholds

• 10:07–11:13 — UVA vs UVB mitochondrial signatures: oxidative photosensitization vs acute direct lesions

• 11:18–12:31 — Apoptosis pathway: BCL-2/BAX shift → membrane permeabilization → cytochrome c → caspases

• 12:41–13:49 — Mitophagy (PINK1/Parkin) as the “clean-up” that prevents chronic ROS amplification

• 14:05–15:44 — Newer nodes: exosomes; ATAD3A/3B; STAT3 and p53 as stress-response architecture

• 15:59–19:06 — Intervention landscape: antioxidant defenses + mitochondria-targeting (MitoQ), peptides, exosomes, melatonin

• 19:13–21:24 — The practical conclusion: wrinkles/pigment/laxity as endpoints of mitochondrial injury; restoration > masking

-

Dr. Mike's #1 recommendations:

Deuterium depleted water: Litewater (code: DRMIKE)

EMF-mitigating products: Somavedic (code: BIOLIGHT)

Blue light blocking glasses: Ra Optics (code: BIOLIGHT)

Grounding products: Earthing.com

-

Stay up-to-date on social media:

Dr. Mike Belkowski:

Instagram

LinkedIn

 

BioLight:

Website

Instagram

YouTube

Facebook

AMD Starts in the Mitochondria: The Hidden Quality-Control Failure Driving Retinal Aging

This Deep Dive reframes age-related macular degeneration (AMD) as more than “aging eyes” or vascular/inflammatory drift. The core argument: AMD may be a mitochondrial quality-control disease, especially in the retinal pigment epithelium (RPE), which is the high-demand support layer that keeps photoreceptors alive. As mitochondrial dynamics break down (excess fission, reduced fusion, reduced biogenesis, failing mitophagy), damaged mitochondria accumulate, ROS rises, mitochondrial danger signals spill into immune pathways, and complement activation becomes chronic — creating a self-reinforcing loop that ends in RPE failure and photoreceptor loss. The most important implication is timing: by the time structural damage is visible, the energetic failure has likely been unfolding for years, meaning the real therapeutic window may be earlier, at the level of mitochondrial resilience.

(Educational content only, not medical advice.)

-

Article Discussed in Episode:

Mitochondrial dynamics and their role in the pathogenesis of age-related macular degeneration: A comprehensive review

-

Key Quotes From Dr. Mike:

“(This article) frames AMD as a disease of mitochondrial breakdown... More specifically, it frames AMD as a disease of failed mitochondrial quality control.”

“This is where the paper becomes especially powerful… it treats it as a central engine of the disease process.”

“The retina has very little room for error.”

“By the time you are looking at advanced dry AMD… the visible anatomy is already reflecting a much older, energetic failure.”

“If we want to preserve vision, we may need to preserve mitochondrial intelligence first.”

-

Key Points

• AMD is framed as mitochondrial breakdown, not just “wear and tear” or late-stage anatomy.

• The RPE is the key vulnerability hub: heavy workload + high oxidative environment = little margin for error.

• “Mitochondrial dynamics” = fission, fusion, biogenesis, mitophagy (quality control).

• AMD models show hyper-fission (DRP1-driven) → fragmented mitochondria → ↓ATP, ↑ROS.

• Reduced fusion proteins (mitofusins/OPA1) → less network repair, less crista stability.

• Downregulated biogenesis (PGC-1α signaling) → fewer healthy replacements when demand is highest.

• Mitophagy failure (PINK1/Parkin bottleneck + lysosomal decline) → damaged mitochondria accumulate.

• Accumulated damage releases mitochondrial DAMPs → cGAS–STING / TLR9 → cytokines + complementamplification.

• Evidence cited includes RPE structural abnormalities, mtDNA mutations/deletions, and metabolite/protein signature shifts.

• Therapy direction: mitochondria-targeted antioxidants (MitoQ/SKQ1), dynamics modulation (DRP1 inhibition), biogenesis/mitophagy support (NAD precursors), membrane stabilization (elamipretide), and future gene therapy nodes (OPA1/TFAM) — with precision + delivery challenges.

-

Episode timeline

• 0:19–1:27 — Why this paper matters: AMD reframed as mitochondrial quality-control failure

• 1:35–2:50 — The RPE: the metabolic “support system” behind vision (why RPE failure is catastrophic)

• 3:00–4:49 — Mitochondrial dynamics in plain English: fission, fusion, biogenesis, mitophagy

• 5:01–5:54 — Risk convergence: aging + genetics + smoking + oxidative burden → mitochondrial vulnerability

• 5:59–7:35 — Fission/fusion imbalance: DRP1 hyper-fission + reduced fusion proteins

• 7:36–8:33 — Biogenesis decline: PGC-1α downregulation and loss of replacement capacity

• 8:33–10:07 — Mitophagy failure: PINK1/Parkin early compensation → chronic bottleneck → accumulation

• 10:11–12:10 — The disease engine: ROS + DAMPs → innate immunity + complement → more damage (vicious cycle)

• 12:32–13:41 — Tissue-level consequences: RPE can’t support photoreceptors → retinal degeneration

• 13:47–14:59 — Human evidence + biomarkers: mtDNA changes, structural disruption, metabolite signals

• 15:00–17:52 — Therapeutic directions: mitochondrial antioxidants, dynamics modulation, mitophagy/biogenesis support, elamipretide, gene targets

• 17:52–20:18 — Precision medicine lens: AMD heterogeneity + “mitochondrial phenotype” concept + closing takeaway

-

Dr. Mike's #1 recommendations:

Deuterium depleted water: Litewater (code: DRMIKE)

EMF-mitigating products: Somavedic (code: BIOLIGHT)

Blue light blocking glasses: Ra Optics (code: BIOLIGHT)

Grounding products: Earthing.com

-

Stay up-to-date on social media:

Dr. Mike Belkowski:

Instagram

LinkedIn

 

BioLight:

Website

Instagram

YouTube

Facebook

Smarter Than Mouthwash: Methylene Blue + Red Light Therapy for Oral Infections

Oral infections aren’t “just a mouth problem” — they’re biofilm problems, delivery problems, and resistance problems. This Deep Dive breaks down a review on photosensitized methylene blue nanoparticles as a next-generation approach for controlling oral pathogens. Instead of relying on free methylene blue (which can disperse fast, stain, and fall short in biofilms), the paper explores methylcellulose nanoparticles engineered for near-complete encapsulation, tunable particle size, and sustained release, then activated with 660 nm light to generate microbe-killing reactive oxygen species. The key takeaway: the future of photodynamic therapy in dentistry won’t be driven by light alone — it’ll be driven by smarter delivery systems that improve retention, penetration, and precision.

(Educational content only, not medical advice.)

-

Article Discussed in Episode:

Photosensitized Methylene Blue Nanoparticles: A Promising Approach for the Control of Oral Infections

-

Key Quotes From Dr. Mike:

“Oral infections are not small issues… the mouth is one of the most microbially active environments in the body.”

“Biofilms are one of the hardest clinical realities in oral medicine.”

“Once biofilms mature, conventional antimicrobial approaches often start to lose efficiency.”

“This paper is focused… using methylene blue not as a free dye in solution but encapsulated inside methyl cellulose nanoparticles.”

“You are no longer just asking whether methylene blue works. You are asking how to shape its behavior in time.”

“The nanoparticles performed better than pure methylene blue.”

-

Key Points

• Oral infections are biofilm-driven and often become harder to treat as biofilms mature.

• The paper asks: can nanoparticle delivery make methylene blue more stable, better retained, and more effective?

• Near-100% encapsulation efficiency suggests the payload is actually protected inside the carrier.

• Loaded particles measured roughly 186–274 nm; smaller/more uniform particles are positioned for stronger interaction and faster release.

• Sustained release >10 hours and tunable behavior: smaller particles released far more MB over the same window than larger ones.

• In antimicrobial testing, MB nanoparticles outperformed free methylene blue (especially with light activation), sometimes dropping counts below detection.

• Mechanism: 660 nm activation → ROS (singlet oxygen/free radicals) → microbial membrane/protein/DNA damage.

• Nanometric size may aid biofilm penetration and increase membrane interaction/permeability.

• Practical dentistry nuance: staining + clinical usability matter, not just kill power.

• Biocompatibility signals a dose-dependent therapeutic window — effective locally, but concentration must be optimized.

-

Episode timeline

• 0:19–1:29 — Framing: why this paper matters (precision + delivery, not just killing microbes)

• 1:37–2:20 — The real problem: dysbiosis, biofilms, persistence, and resistance

• 2:39–3:59 — The central idea: methylene blue as a photosensitizer, upgraded via nanoparticles

• 4:04–6:48 — Build + characterization: encapsulation efficiency, particle size, uniformity, morphology

• 7:15–8:49 — Release profile: sustained delivery and tunable behavior by particle size

• 8:55–12:44 — Antimicrobial results: broad pathogen panel, nanoparticles outperform free MB + PDT mechanism

• 12:51–13:42 — Dentistry reality check: staining, patient tolerance, real-world usability

• 13:45–15:13 — Biocompatibility: dose-dependent cytotoxicity and therapeutic window concept

• 15:17–17:49 — Big conclusion: “delivery is the therapy,” and why this aligns with BioLight’s systems mindset

• 17:49–18:03 — Close: the future of PDT = light + smarter delivery

-

Dr. Mike's #1 recommendations:

Deuterium depleted water: Litewater (code: DRMIKE)

EMF-mitigating products: Somavedic (code: BIOLIGHT)

Blue light blocking glasses: Ra Optics (code: BIOLIGHT)

Grounding products: Earthing.com

-

Stay up-to-date on social media:

Dr. Mike Belkowski:

Instagram

LinkedIn

 

BioLight:

Website

Instagram

YouTube

Facebook

Your Mitochondria Have a Schedule: Why Energy Is a Timing Problem (Not a Fuel Problem)

Most people think circadian rhythm is just “sleep timing.” This Deep Dive flips that model on its head using a plant biology review with a human-relevant message: energy is not just about fuel — energy is about timing. The circadian clock doesn’t simply respond to sunlight; it’s shaped from the inside by metabolic cues from chloroplasts and mitochondria — sugars, redox state, ROS, organic acids, and cellular energy status. The result is a living loop: light tunes metabolism, metabolism tunes the clock, and the clock re-schedules metabolism. The real takeaway: resilience isn’t rigid perfection, it’s coordinated complexity.

(Educational content only, not medical advice.)

-

Article Discussed in Episode:

Metabolism in Sync: The Circadian Clock, a Central Hub for Light-Driven Chloroplastic and Mitochondrial Entrainment

-

Key Quotes From Dr. Mike:

“Energy is not just about having fuel. Energy is also about timing.”

“The circadian system is not simply being pushed around by light from the outside.”

“The chloroplast is not just a photosynthetic organelle, it is also a timing organelle.”

“Mitochondria are not only engines, they are sensors.”

“The goal is not to eliminate ROS entirely. The goal is rhythmic redox balance.”

“Living systems do not thrive simply because they have energy. They thrive because they know how to coordinate energy in time.”

-

Key Points

• Energy is timing, not just fuel: healthy biology anticipates; it doesn’t only react.

• Circadian rhythm is a loop: the clock regulates metabolism and metabolism feeds back into the clock.

• Metabolism is information: sugars, redox shifts, ROS, ATP availability, and organic acids act as timing cues.

• Sugar can “set” the clock: even in darkness, sucrose can sustain rhythmic clock gene expression—and timing of sucrose shifts the phase.

• Chloroplasts + mitochondria aren’t just workers: they’re active participants in circadian entrainment and timing signals.

• Rhythmic redox balance matters: the goal isn’t “no ROS,” it’s controlled, rhythmic ROS + rhythmic antioxidant defense.

• Coordination beats optimization: efficiency comes from synchronizing interdependent processes (e.g., photorespiration across organelles).

• Big implication: what matters is not only what input you provide, but when the organism is most prepared to use it (chronoculture).

-

Episode timeline

• 0:19–1:18 — Framing: plant paper, human lesson—energy is timing

• 1:33–2:37 — The core loop: clock ↔ metabolism (not one-way light → clock → metabolism)

• 2:50–3:55 — Plants as master adapters: predictive physiology via circadian intelligence

• 4:44–5:14 — Key pivot: light entrains, but the clock persists beyond photoreceptors

• 5:14–7:30 — Metabolism as a timing signal (sucrose as phase-setter; roots “see” sugar)

• 7:43–10:16 — Chloroplasts + mitochondria: scheduled by the clock, but also feeding signals back

• 10:19–11:56 — Mitochondrial scheduling + feedback: transcripts, metabolites, stress signals alter rhythm

• 12:06–13:11 — Inter-organelle coordination: photorespiration as a synchronized, multi-compartment pathway

• 13:20–15:42 — ROS nuance: rhythmic ROS/antioxidant alignment; sugar → ROS → clock

• 15:42–16:39 — “Three-body problem” analogy: coordinated complexity = resilience

• 16:39–17:46 — Practical implications: agriculture, domestication, chronoculture; timing inputs to readiness

• 17:52–18:59 — Closing thesis: life thrives by orchestrating energy in time

-

Dr. Mike's #1 recommendations:

Deuterium depleted water: Litewater (code: DRMIKE)

EMF-mitigating products: Somavedic (code: BIOLIGHT)

Blue light blocking glasses: Ra Optics (code: BIOLIGHT)

Grounding products: Earthing.com

-

Stay up-to-date on social media:

Dr. Mike Belkowski:

Instagram

LinkedIn

 

BioLight:

Website

Instagram

YouTube

Facebook

Light Over the Thyroid: Can PBM Improve Fatigue, Sleep, Mood, and Pain in Hashimoto’s?

Hashimoto’s thyroiditis is usually treated like a numbers problem: TSH normalizes, levothyroxine is “working,” end of story. But many patients live in a different reality: persistent fatigue, poor sleep, brain fog, low mood, pain, and a feeling of being drained even when labs look fine.

In this Deep Dive, Dr. Mike breaks down a study that tested photobiomodulation (PBM) applied over the thyroid region as an adjunct to standard treatment. The key focus wasn’t just lab values — it was how people actually felt: fatigue severity, fatigue impact, sleep quality, daytime sleepiness, anxiety, depression, and pain. Both sham and active groups improved (placebo and therapeutic attention are real), but the active PBM group improved more across every major symptom category, suggesting a broader shift in underlying physiology — likely involving mitochondrial function, oxidative stress, and inflammatory signaling.

Bottom line: this isn’t “light replaces medicine.” It’s a serious look at what happens when replacement therapy corrects a piece of the picture, but the energetic terrain still needs support.

(Educational content only, not medical advice.)

-

Article Discussed in Episode:

The effect of photobiomodulation therapy on fatigue and behavioural status in patients with Hashimoto’s thyroiditis

-

Key Quotes From Dr. Mike:

"This paper doesn’t frame Hashimoto’s only as a hormone problem — it points to inflammation, oxidative stress, and mitochondrial dysfunction.”

“The active photobiomodulation group improved more; across every major symptom category measured.”

“When you see energy, mood, sleep, and pain shift together, you’re not looking at a narrow effect — you’re looking at a deeper physiological influence.”

“Hormone replacement may correct part of the picture, but not always restore cellular energy dynamics.”

“Healing isn’t just bringing a number into range. Healing is restoring function.”

-

Key Points

• Hashimoto’s isn’t only a hormone story — persistent symptoms may reflect inflammation, oxidative stress, and mitochondrial strain even when labs normalize.

• Study design: PBM + levothyroxine vs sham + levothyroxine, applied over the thyroid region 2x/week for 3 weeks.

• Outcomes prioritized real life symptoms: fatigue (severity + impact), sleep quality, daytime sleepiness, anxiety, depression, pain.

• Both groups improved, reinforcing the role of expectation/attention/placebo.

• Active PBM improved more across all main symptom categories measured.

• Mechanistic framing: PBM may support mitochondrial respiration/ATP, modulate ROS, reduce oxidative stress, and influence cytokines/inflammation.

• Improvements in sleep + mood matter because they often drive the entire “fatigue spiral.”

• This is not a cure study and not definitive for long-term outcomes, but it’s clinically meaningful because it targets what patients actually report.

• Core message: numbers can improve while function lags — and function is the point.

-

Episode timeline

• 0:19 – 0:55 Intro + the core problem: Hashimoto’s patients still feel bad even with “better labs”

• 0:55 – 2:16 Why standard care can fall short: symptoms persist despite levothyroxine normalization

• 2:16 – 3:17 BioLight lens: inflammation, oxidative stress, mitochondrial dysfunction as the “missing layer”

• 3:17 – 4:36 Study setup: PBM over thyroid region, randomized groups, symptom-focused outcomes

• 4:41 – 5:33 Results: both groups improved, but active PBM improved more across the board

• 5:55 – 7:50 Mechanism discussion: mitochondria/ATP, ROS signaling, oxidative stress, immune modulation

• 8:19 – 10:14 Mood + sleep: why improvements here suggest systemic regulation, not a narrow effect

• 10:16 – 11:14 Grounding + limitations: not a huge trial, sham improved, don’t overclaim

• 11:14 – 13:29 Practical meaning: restoring function, resilience, and “vitality outcomes”

-

Dr. Mike's #1 recommendations:

Deuterium depleted water: Litewater (code: DRMIKE)

EMF-mitigating products: Somavedic (code: BIOLIGHT)

Blue light blocking glasses: Ra Optics (code: BIOLIGHT)

Grounding products: Earthing.com

-

Stay up-to-date on social media:

Dr. Mike Belkowski:

Instagram

LinkedIn

 

BioLight:

Website

Instagram

YouTube

Facebook

Calories Are the Surface. Mitochondria Are the Story: The Real Science of Weight Loss

Most weight-loss advice stops at “calories in vs. calories out.” In this episode, Dr. Mike goes deeper: what happens to your body’s energy machinery during weight loss and why maintenance can be harder than the initial drop. Using four papers (two skeletal muscle mitochondrial studies, one PBM body-contouring study, and one chlorin e6 photodynamic obesity study in mice), you’ll learn how weight loss can lower energy expenditure, remodel mitochondrial membranes (cardiolipin), shift efficiency and coupling, and produce totally different adaptations depending on whether the weight came off via lifestyle or bariatric surgery. The headline: weight loss is an adaptive bioenergetic event, not just a subtraction problem — and mitochondria sit in the middle of the outcome.

(Educational content only, not medical advice.)

-

Articles Discussed in Episode:

Human Skeletal Muscle Mitochondria Responses to Weight Loss Induced by Bariatric Surgery or Lifestyle Intervention

Weight loss increases skeletal muscle mitochondrial energy efficiency in obese mice

Photobiomodulation Therapy for Improvement of Body Contour: A Retrospective Study on Middle Eastern Participants

Anti-Obesity Effect of Chlorin e6-Mediated Photodynamic Therapy on Mice with High-Fat-Diet-Induced Obesity

-

Key Quotes From Dr. Mike:

“Body composition is downstream of energy biology.”

“Weight loss is not just a subtraction problem, it’s an adaptive biological event.”

“After weight loss, the body isn’t just smaller — it’s more economical.”

“Maintenance is part of the weight-loss intervention, not the chapter after.”

“Don’t just ask whether something helps you lose weight—ask what it teaches your body to do with energy.”

-

Key Points

• Weight loss ≠ simple subtraction: it triggers adaptive biology (hormones, fuel use, expenditure, defense mechanisms).

• Mitochondria are central: not just ATP—also redox regulation, signaling, substrate use, heat generation, stress response.

• Post-weight-loss “efficiency” can backfire: more efficient mitochondria can mean lower energy expenditure, making maintenance harder.

• Membrane biology matters: cardiolipin remodeling (e.g., tetralinoleoyl cardiolipin) may tune oxidative phosphorylation efficiency.

• Route matters: bariatric surgery vs lifestyle weight loss can produce different mitochondrial signatures despite both lowering scale weight.

• Function > quantity: improvements can show up as better respiration/coupling without “more mitochondria” or big morphology changes.

• Body contouring ≠ metabolic transformation: local circumference changes can occur without BMI shifts—different level of outcome.

• PBM vs PDT are not the same: photodynamic therapy (chlorin e6 + light) is a more aggressive tool than classic PBM “signaling.”

• Adaptive compensation is the hidden driver: hunger, expenditure, fuel partitioning, and tissue signaling shift to resist depletion.

• Better question: not “did you lose weight?” but “what adaptation did your strategy create?”

-

Episode timeline

00:00 – 02:00 | The myth of “just do the math” | Why energy balance matters, but isn’t the full story. Weight loss as an adaptive event.

02:00 – 06:00 | Reframing mitochondria | Mitochondria as energy transducers + redox/signaling hubs that determine how the body handles fuel.

06:00 – 18:00 | Paper #1 (Obese mice): efficiency rises after weight loss | Lower whole-body expenditure + more efficient oxidative phosphorylation. Why “better fuel economy” can become “metabolic conservation.”

18:00 – 23:00 | Cardiolipin and TLCL: the membrane-level shift | How mitochondrial inner membrane lipids (cardiolipin remodeling) may tune efficiency and what tafazzin-related findings imply.

23:00 – 34:00 | Paper #4 (Humans): surgery vs lifestyle creates different mitochondrial outcomes | Weight loss route changes mitochondrial respiration/proteome responses; diabetes status adds individual variability.

34:00 – 41:00 | Paper #2 (Humans): PBM + contouring outcomes | Circumference changes vs BMI stability — why body contouring isn’t the same as systemic metabolic repair.

41:00 – 49:00 | Paper #3 (Mice): chlorin e6 photodynamic “anti-obesity” effects | PDT vs PBM distinction; broader obesity marker shifts in an animal model; interesting, but not a protocol permission slip.

49:00 – End | Synthesis: weight loss is energy reprogramming | The unified framework: adaptive bioenergetics, maintenance as part of the intervention, and the “optimize for what?” question.

-

Dr. Mike's #1 recommendations:

Deuterium depleted water: Litewater (code: DRMIKE)

EMF-mitigating products: Somavedic (code: BIOLIGHT)

Blue light blocking glasses: Ra Optics (code: BIOLIGHT)

Grounding products: Earthing.com

-

Stay up-to-date on social media:

Dr. Mike Belkowski:

Instagram

LinkedIn

 

BioLight:

Website

Instagram

YouTube

Facebook

Does Red Light to the Brain Boost Endurance In Trained Cyclists? What the Data Actually Says

Transcranial photobiomodulation (tPBM) is everywhere in performance culture —shine near-infrared light on the prefrontal cortex and supposedly you get better oxygenation, lower perceived effort, delayed central fatigue, and improved endurance. This Deep Dive episode breaks down a clean, double-blind crossover study in trained cyclists who rode their own bikes through a standardized constant-load effort followed by a 25-minute time trial. The conclusion was clear: acute tPBM at 810nm (40Hz, 20 minutes, with an intranasal component) did not improve performance, heart rate, lactate, perceived exertion, or pacing dynamics versus sham. The real value is what the null result teaches: dose, penetration, target engagement, and context matter —especially in trained athletes.

(Educational content only, not medical advice.)

-

Article Discussed in Episode:

Effects of transcranial photobiomodulation on performance and cardiovascular responses in trained cyclists

-

Key Quotes From Dr. Mike:

“Does it (tPBM) actually work in real athletes under real performance conditions with real outcomes like power, heart rate, and pacing?”

“Can enough light penetrate scalp and skull to meaningfully modulate cortical function?”

“Parameters matter, penetration matters, and athletes are a hard population to move.”

“Wavelength and irradiance aren’t specs for marketing — they’re the difference between signal and nothing.”

-

Key Points

• Clean test of hype: trained cyclists, double-blind, randomized crossover, real performance outcomes.

• Protocol: 20 min tPBM (810nm, 40Hz; prefrontal targeting + intranasal probe), then warm-up → 15-min constant load → 25-min time trial.

• Result: no meaningful differences vs sham in power, HR, lactate, RPE, or efficiency-style ratios.

• Likely explanations: insufficient cortical photon dose/penetration, parameter selection (wavelength/irradiance), acute vs chronic effects, no direct confirmation of brain “target engagement,” athlete ceiling effects.

• Takeaway: null results are useful—optimize parameters, verify engagement (fNIRS/EEG), test chronic protocols, and match outcomes to what the PFC actually influences (pacing decisions, inhibition, interoception).

-

Episode timeline

• 0:19–1:42 — The promise vs the test: trained cyclists + double-blind crossover; headline null result

• 1:59–3:27 — Why tPBM could work: mitochondria, CCO, ATP/NO/redox; PFC role in pacing & effort

• 3:28–4:55 — The real question: can enough light reach cortex in trained athletes? Study design + protocol

• 5:13–5:59 — What they measured: HR, lactate, RPE, time-trial power, power/HR and power/RPE trends

• 6:10–7:35 — Results: expected fatigue drift in both blocks, no separation between PBM and sham

• 7:44–10:52 — Why it may have failed: penetration, dosimetry, wavelength, acute vs chronic, ceiling effect

• 10:57–11:59 — What good science does: treat null as signal; what to optimize next

• 12:05–13:56 — BioLite lens: tissue accessibility vs skull barrier; “systems not magic”; stack fundamentals

• 14:02–15:17 — Closing: what the study proves (and what it doesn’t); next episode tease

-

Dr. Mike's #1 recommendations:

Deuterium depleted water: Litewater (code: DRMIKE)

EMF-mitigating products: Somavedic (code: BIOLIGHT)

Blue light blocking glasses: Ra Optics (code: BIOLIGHT)

Grounding products: Earthing.com

-

Stay up-to-date on social media:

Dr. Mike Belkowski:

Instagram

LinkedIn

 

BioLight:

Website

Instagram

YouTube

Facebook

Can Red Light Actually Lower Blood Sugar? Early Clinical Trials Suggest a Real Signal (Not a Miracle)

Can photobiomodulation (red + near-infrared light) meaningfully improve glycemic control in people with type 2 diabetes? In this Deep Dive, Dr. Mike Belkowski breaks down a 2026 systematic review of randomized clinical trials that tested PBM for diabetes outcomes like fasting glucose, post-prandial glucose, and HbA1c.

The evidence base is small — only 4 RCTs met strict inclusion criteria (control/sham required) — but the signal was generally favorable: PBM was associated with reductions in fasting glucose, post-prandial glucose, and HbA1c, and in some studies improvements in lipid markers. The catch is that overall certainty is very low to low due to small samples, protocol heterogeneity, and bias concerns. Translation: promising adjunct, not proven therapy, and not remotely a replacement for standard care.

(Educational content only, not medical advice.)

-

Article Discussed in Episode:

Photobiomodulation Therapy to Improve Glycemic Control in People with Diabetes Mellitus: A Systematic Review

-

Key Quotes From Dr. Mike:

“Type 2 diabetes… chronic hyperglycemia disrupts mitochondrial metabolism, increases oxidative stress, activates inflammatory pathways…”

“PBM, mostly red and near infrared wavelengths, was associated with reductions in fasting glucose, postprandial glucose, and HBA1C.”

“These were longer protocols, 30 minutes per session, 3 sessions per week for 12 weeks.”

“PBM is not a replacement for medication, nutrition, exercise, or medical monitoring.”

“We’re early, but the direction is real.”

-

Key Points

• The review included 4 randomized clinical trials (1993–2025 search; control/sham required).

• Outcomes emphasized fasting glucose, post-prandial glucose, HbA1c, plus some cardiometabolic measures.

• Overall finding: PBM was generally associated with improved glycemic markers, sometimes lipids too.

• Evidence certainty: very low to low (small N, heterogeneity, some risk-of-bias concerns).

• Protocol types:

  • Wrist “watch” PBM over radial pulse area: 30 min, 3x/week, 12 weeks, often alongside meds.

  • LED pad PBM over large tissue regions (limbs/abdomen): crossover, sham-controlled, acute/time-response.

   

• Dose response looks biphasic (a “sweet spot”): one trial found 100 J sustained lower glycemia up to 12 hours, while higher dose wasn’t clearly better.

• Mechanistic framework: mitochondria/CCO, NO & microcirculation, ROS → Ca²⁺ → AMPK, and GLUT4 translocation.

• Bottom line: PBM is a plausible metabolic signal and an early clinical adjunct candidate—but the field needs larger, standardized RCTs and clearer dose-response mapping.

-

Episode timeline

• 0:19–1:26 — The “futuristic” question + disclaimer (PBM as adjunct, not replacement)

• 1:30–3:20 — Why PBM could matter in T2D (hyperglycemia → mito dysfunction/oxidative stress loop)

• 3:24–4:51 — Systematic review methods + headline result (only 4 RCTs; generally favorable; low certainty)

• 5:04–6:03 — Trial type #1: wrist “watch” PBM over radial pulse (12-week adjunct outcomes)

• 6:03–7:28 — Trial type #2: LED pad PBM over larger tissue areas (crossover; acute/time-response; dose effects)

• 7:28–8:40 — Biphasic response explanation + quality/bias ratings (PEDro, ROB2, GRADE)

• 8:41–10:34 — Mechanisms: bioenergetics, NO/microcirculation, ROS→AMPK, GLUT4

• 10:34–11:58 — Nuance: mixed literature; protocol variability likely drives inconsistent results

• 12:02–13:26 — The Energy Code conclusion: promising adjunct, early evidence, needs standardization

-

Dr. Mike's #1 recommendations:

Deuterium depleted water: Litewater (code: DRMIKE)

EMF-mitigating products: Somavedic (code: BIOLIGHT)

Blue light blocking glasses: Ra Optics (code: BIOLIGHT)

Grounding products: Earthing.com

-

Stay up-to-date on social media:

Dr. Mike Belkowski:

Instagram

LinkedIn

 

BioLight:

Website

Instagram

YouTube

Facebook

Alzheimer’s Isn’t “Just Aging”: Human Brain Data Shows a Distinct Mitochondrial Collapse — Especially in the Hippocampus

Most conversations about Alzheimer’s and mitochondria stay in broad strokes. This Deep Dive episode doesn’t. Dr. Mike Belkowski breaks down a study that examined postmortem human brain tissue to answer a precise question: do mitochondrial electron transport chain proteins shift in Alzheimer’s the same way they shift in normal aging — or is Alzheimer’s a different mitochondrial pattern entirely?

Using three groups (young controls 35–45, aged controls >85 without Alzheimer’s pathology, and sporadic Alzheimer’s cases 85–89), the researchers measured neuron-level immunohistochemical intensity (a proxy for relative protein abundance) for key mitochondrial markers: complex IV subunits MTCO1/MTCO2, complex V (ATP synthase), and IF1, the ATP synthase inhibitory factor that helps prevent catastrophic ATP “backwards burning” during stress and supports crista integrity.

The core finding: Alzheimer’s shows electron transport chain instability that differs from physiological aging, and the hippocampus (CA1/CA2) stands out as a failure zone — losing IF1 and failing to mount the compensatory ATP synthase response seen in other regions. In Energy Code terms: memory circuits are energy-expensive, and Alzheimer’s appears to remove mitochondrial protection exactly where it’s needed most.

(Educational content only, not medical advice.)

-

Article Discussed in Episode:

Immunohistochemical Markers of Mitochondrial Electron Transport Chain Instability in Human Brain Regions: A Study of Aging and Alzheimer’s Disease

-

Key Quotes From Dr. Mike:

“Do the mitochondrial electron transport chain proteins change in Alzheimer’s… or is Alzheimer’s a fundamentally different mitochondrial pattern?”

“Alzheimer’s shows a pattern of mitochondrial electron transport chain instability that is fundamentally distinct from physiological aging.”

“The hippocampus appears to be uniquely vulnerable because it fails to mount a protective compensatory response.”

“Alzheimer’s shows instability, and the hippocampus stands out as a failure zone.”

“Memory circuits depend on mitochondrial resilience… and the hippocampus loses mitochondrial protection exactly where it needs it most.”

-

Key Points

• The study compares young controls, aged controls, and sporadic Alzheimer’s using human brain tissue.

• Multiple regions were analyzed: middle frontal gyrus, anterior cingulate, caudate, hippocampus CA1/CA2, inferior parietal lobule.

• Markers measured (IHC intensity proxy): MTCO1 + MTCO2 (complex IV), complex V (ATP synthase marker), IF1.

• Complex IV subunit imbalance (MTCO1 ↓ while MTCO2 ↑) is repeatedly seen in Alzheimer’s → suggests complex IV stoichiometry/assembly instability and potential ↑electron leak/ROS.

• IF1 matters because it:

  • inhibits reverse ATP hydrolysis by ATP synthase during stress (energy-preserving)

  • supports crista architecture via ATP synthase dimer stabilization

   

• Many cortical regions show Alzheimer’s-associated compensatory increases in complex V and IF1.

• Hippocampus is the exception: IF1 drops and complex V fails to rise → reduced protection against energy collapse.

• Conclusion: Aging ≠ early Alzheimer’s; Alzheimer’s shows a distinct mitochondrial signature, with hippocampal vulnerability linked to failure of adaptive response.

• Limitations: IHC is indirect (protein pattern proxy, not respiration measurements), but the region-specific patterns are coherent.

-

Episode timeline

• 0:19–1:24 — The core question + headline conclusion (Alzheimer’s vs aging mitochondrial pattern)

• 1:26–2:33 — Study design: groups, ages, regions analyzed

• 2:33–3:12 — What they measured: MTCO1, MTCO2, complex V, IF1 (IHC intensity proxy)

• 3:19–5:32 — Why these proteins matter: complex IV roles; ATP synthase; IF1 as protector + crista stabilizer

• 5:34–7:58 — Region-by-region patterns (frontal cortex, anterior cingulate, caudate): instability vs compensation

• 8:02–9:48 — Hippocampus CA1/CA2: the “failure zone” (IF1 down + no complex V compensation)

• 9:57–11:54 — Energy Code synthesis: aging ≠ Alzheimer’s; complex IV instability + hippocampal loss of protection

• 12:01–12:23 — Limitations (IHC proxy vs functional measures)

• 12:26–14:18 — Implications: early mitochondrial stability/quality-control strategy; why memory is hit first

-

Dr. Mike's #1 recommendations:

Deuterium depleted water: Litewater (code: DRMIKE)

EMF-mitigating products: Somavedic (code: BIOLIGHT)

Blue light blocking glasses: Ra Optics (code: BIOLIGHT)

Grounding products: Earthing.com

-

Stay up-to-date on social media:

Dr. Mike Belkowski:

Instagram

LinkedIn

 

BioLight:

Website

Instagram

YouTube

Facebook